Very promising observations were made with the OGG1 competitive inhibitors TH5487 and SU0268 that have been proposed to be potential new tools for cancer therapy (Visnes et al., 2020) and for the treatment of inflammatory diseases (Visnes et al., 2018b; Karsten, 2022). This evidence concerns the gene OGG1 and cancer.